Accelerate Diagnostics Inc
AXDX
Market Cap$13.36M
Close$
$1.86
1249.5% upside
Current Fair Value
1249.5% upsideUndervalued by 1249.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.36 Million |
|---|---|
| Enterprise Value | $63.25 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.15 |
| Beta | 0.46 |
| Outstanding Shares | 23,302,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.25 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | -0.05 |
| Enterprise Value to Revenue | 5.32 |
| Enterprise Value to EBIT | -1.77 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -1.16 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Accelerate Diagnostics Inc
CEO: John Phillips Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several...